NZ588715A - 5-ht3 receptor modulators, methods of making, and use thereof - Google Patents

5-ht3 receptor modulators, methods of making, and use thereof

Info

Publication number
NZ588715A
NZ588715A NZ588715A NZ58871509A NZ588715A NZ 588715 A NZ588715 A NZ 588715A NZ 588715 A NZ588715 A NZ 588715A NZ 58871509 A NZ58871509 A NZ 58871509A NZ 588715 A NZ588715 A NZ 588715A
Authority
NZ
New Zealand
Prior art keywords
disorders
disease
vomiting
compounds
induced nausea
Prior art date
Application number
NZ588715A
Other languages
English (en)
Inventor
David D Manning
Original Assignee
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Res Inc filed Critical Albany Molecular Res Inc
Publication of NZ588715A publication Critical patent/NZ588715A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ588715A 2008-05-29 2009-05-28 5-ht3 receptor modulators, methods of making, and use thereof NZ588715A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5701408P 2008-05-29 2008-05-29
PCT/US2009/045484 WO2009155054A2 (en) 2008-05-29 2009-05-28 5-ht3 receptor modulators, methods of making, and use thereof

Publications (1)

Publication Number Publication Date
NZ588715A true NZ588715A (en) 2012-11-30

Family

ID=41380582

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ588715A NZ588715A (en) 2008-05-29 2009-05-28 5-ht3 receptor modulators, methods of making, and use thereof

Country Status (12)

Country Link
US (3) US8124600B2 (enExample)
EP (1) EP2310019A4 (enExample)
JP (1) JP5465241B2 (enExample)
KR (1) KR101653707B1 (enExample)
CN (1) CN102046176B (enExample)
AU (1) AU2009260469B2 (enExample)
BR (1) BRPI0913188A2 (enExample)
CA (1) CA2724449C (enExample)
IL (1) IL208939A (enExample)
MX (1) MX2010012807A (enExample)
NZ (1) NZ588715A (enExample)
WO (1) WO2009155054A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528225B (zh) * 2006-08-07 2013-07-17 阿尔巴尼分子研究公司 作为5ht3调节剂的2-氨基苯并噁唑羧酰胺
JP5663572B2 (ja) * 2009-07-14 2015-02-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ｈｔ３受容体モジュレーター、その作製方法、およびその使用
AU2011291506B2 (en) 2010-08-19 2016-07-28 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
WO2012109446A1 (en) * 2011-02-09 2012-08-16 Andrew, Llc System and method for location boosting using proximity information
US20150165045A1 (en) * 2012-07-06 2015-06-18 Pharmathen S.A. Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
WO2014114734A1 (en) * 2013-01-25 2014-07-31 Universitat De Barcelona Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment
CN106795172B (zh) * 2014-09-29 2020-07-28 武田药品工业株式会社 1-(1-甲基-1h-吡唑-4-基)-n-((1r,5s,7s)-9-甲基-3-氧杂-9-氮杂双环[3.3.1]壬-7-基)-1h-吲哚-3-甲酰胺的晶型
CN107233351A (zh) * 2017-06-07 2017-10-10 新乡医学院 一种治疗阿尔海默式综合症的药物组合物及应用
EP3856172A4 (en) * 2018-09-28 2022-10-05 Visceral Therapeutics Inc. PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF GASTROINTESTINAL CONDITIONS
CN111825702A (zh) * 2019-04-22 2020-10-27 成都科岭源医药技术有限公司 一种氮杂*并吲唑类衍生物及其制备方法和用途
CN112390799B (zh) * 2019-08-16 2022-04-29 科岭源生物科技(深圳)有限公司 一种含氮杂环类5-ht3受体调节剂及其制备方法和用途
JP2023520164A (ja) * 2020-03-16 2023-05-16 チョンドゥー サイマウント ファーマテック カンパニー リミテッド ５－ｈｔ３受容体モジュレーター、結晶形態、それらの製造方法及び使用
WO2022110052A1 (zh) * 2020-11-27 2022-06-02 科岭源生物科技(深圳)有限公司 一种含氮杂环类5-ht3受体调节剂及其制备方法和用途
CA3176091C (en) * 2020-12-31 2023-07-25 1280225 B.C. Ltd. Method of synthesizing indole compounds
CN116173039B (zh) * 2021-11-26 2024-05-24 科岭源生物科技(深圳)有限公司 一种治疗肠易激综合征的药物组合物及其制备方法
CN117105958B (zh) * 2022-05-24 2025-08-29 科岭源生物科技(深圳)有限公司 一种制备5-ht3受体调节剂的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE3810552A1 (de) * 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
AU7618991A (en) 1990-05-14 1991-11-14 Syntex (U.S.A.) Inc. Novel tricyclic compounds
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5756514A (en) * 1996-08-22 1998-05-26 Larijani; Ghassem E. Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
MXPA03004832A (es) 2000-12-01 2004-05-04 Guilford Pharm Inc Compuestos y sus usos.
CA2447156A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
US6770655B2 (en) 2002-01-18 2004-08-03 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
US6906096B2 (en) 2002-06-28 2005-06-14 Irm Llc 4,7-Disubstituted indoles and methods of making
EP1638560A1 (en) * 2003-06-20 2006-03-29 Eli Lilly And Company 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
JP2007510708A (ja) 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
KR20050062940A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
US7910621B2 (en) 2004-03-22 2011-03-22 The Regents Of The University Of Michigan Small molecule antagonists of XIAP family proteins
WO2006028161A1 (ja) * 2004-09-09 2006-03-16 Research Foundation Itsuu Laboratory セロトニン５－ｈｔ３受容体作動薬
RU2007134414A (ru) 2005-02-17 2009-03-27 Амр Текнолоджи, Инк. (Us) Бензоксазолкарбоксамиды для лечения индуцированной химиотерапией тошноты и рвоты (cini) и синдрома раздраженного кишечника с преобладанием диареи (ibs-d)
AU2006279034A1 (en) * 2005-08-05 2007-02-15 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
WO2007098418A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US20070259933A1 (en) 2006-05-04 2007-11-08 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
US7553846B2 (en) 2006-08-07 2009-06-30 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5-HT3 modulators
CN101528225B (zh) 2006-08-07 2013-07-17 阿尔巴尼分子研究公司 作为5ht3调节剂的2-氨基苯并噁唑羧酰胺
JP2010520917A (ja) 2007-03-13 2010-06-17 ビオヴィトルム・アクチボラゲット（プブリクト） 肥満治療用三環式イソキノリン誘導体
JP5663572B2 (ja) 2009-07-14 2015-02-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ｈｔ３受容体モジュレーター、その作製方法、およびその使用

Also Published As

Publication number Publication date
US8501729B2 (en) 2013-08-06
AU2009260469B2 (en) 2014-02-13
CA2724449C (en) 2017-05-30
KR20110021837A (ko) 2011-03-04
US8710047B2 (en) 2014-04-29
US20130310366A1 (en) 2013-11-21
KR101653707B1 (ko) 2016-09-02
WO2009155054A2 (en) 2009-12-23
CA2724449A1 (en) 2009-12-23
US20120219641A1 (en) 2012-08-30
WO2009155054A3 (en) 2010-02-18
US20090298809A1 (en) 2009-12-03
MX2010012807A (es) 2010-12-21
CN102046176A (zh) 2011-05-04
IL208939A (en) 2015-09-24
BRPI0913188A2 (pt) 2016-01-12
EP2310019A2 (en) 2011-04-20
AU2009260469A1 (en) 2009-12-23
CN102046176B (zh) 2013-08-07
JP2011521963A (ja) 2011-07-28
EP2310019A4 (en) 2011-06-01
IL208939A0 (en) 2011-01-31
US8124600B2 (en) 2012-02-28
JP5465241B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
EA201500402A1 (ru) Гетероароматические соединения в качестве лигандов допамина d1
JOP20210064B1 (ar) طريقة لانتاج ( z)-ألفا-فلورو-بيتا-أمينو-أكريل الدهيدات مستبدلة
CU20150180A7 (es) Piridin-2 que contienen il-4-derivados sustituidos de 1-diazino fenilo útiles como ligandos de dopamina
WO2012054364A3 (en) Bicyclic diamines as janus kinase inhibitors
JP2011521963A5 (enExample)
MX340696B (es) Anticuerpos anti-c5a y metodos para usar los anticuerpos.
MX2015017491A (es) Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona.
JP2015536307A5 (enExample)
JP2014029453A5 (enExample)
EP2643732A4 (en) PROCESS FOR FORMING AN UNEQUAL STRUCTURE ON THE SURFACE OF A SURFACE LAYER OF A CYLINDRICAL ELECTROPHOTOGRAPHIC ELEMENT, AND PROCESS FOR PRODUCING A CYLINDRICAL ELECTROPHOTOGRAPHIC PHOTOSENSITIVE ELEMENT HAVING AN UNEQUAL STRUCTURE FORMED ON THE SURFACE OF ITS SURFACE LAYER
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
JP2009538867A5 (enExample)
EP2690123A4 (en) POLYIMIDE PROCESSING SOLUTION, POLYIMIDE PROCESSOR, POLYIMIDE RESIN, MUD MIXTURE, ELECTRODE, METHOD FOR THE PREPARATION OF THE SLUDGE MIXTURE AND ELECTRODE FORMING METHOD
EA201101188A1 (ru) [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TN2011000319A1 (en) Substituted quinazoline compounds
EP2535444A4 (en) METHOD FOR PRODUCING A SILICON CARBIDE CRYSTAL AND SILICON CARBIDE CRYSTAL
EP2927733A4 (en) EYE GLASS, MANUFACTURING DEVICE AND PRODUCTION METHOD FOR A GLASS GLASS
NZ614567A (en) Novel compounds as histamine h3 receptor ligands
WO2012101652A3 (en) A novel process for synthesis of polyphenols
SG11201404047QA (en) Polishing composition, manufacturing process therefor, process for production of silicon substrate, and silicon substrate
MD4622B1 (ro) Minigranule cu eliberare prelungită a trimetazidinei
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands
RU2010135037A (ru) Новые производные, 1,4-диазабицикло[3.2.2]нонилоксадиазолил, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ALBANY MOLECULAR RESEARCH, INC., US

Free format text: OLD OWNER(S): ALBANY MOLECULAR RESEARCH, INC.; DAVID D. MANNING; CHRISTOPHER LAWRENCE CIOFFI CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE D'AIXMARSEILLE

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 MAY 2016 BY CPA GLOBAL

Effective date: 20130412

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2017 BY CPA GLOBAL

Effective date: 20160415

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2018 BY CPA GLOBAL

Effective date: 20170418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2019 BY ACUMASS

Effective date: 20180514

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2020 BY JAMES + WELLS

Effective date: 20190521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2021 BY IPAN GMBH

Effective date: 20200518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2022 BY IPAN GMBH

Effective date: 20210517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2023 BY IPAN GMBH

Effective date: 20220516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2024 BY IPAN GMBH

Effective date: 20230515

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2025 BY IPAN GMBH

Effective date: 20240514

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2026 BY IPAN GMBH

Effective date: 20250514